A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome

Hereditary Cancer in Clinical Practice

Mary Stanley Beattie¹  Eleanor Cheung⁵  Jennifer Creasman²  Julia Fehniger³  Ani Kardashian⁴ 

[1] Department of Medicine, University of California San Francisco, 94143 San Francisco, CA, USA;Department of Obstetrics and Gynecology, University of California San Francisco, 94143 San Francisco, CA, USA;University of Michigan Medical School, 48109 Ann Arbor, MI, USA;University of California San Francisco Cancer Risk Program, 94115 San Francisco, CA, USA;Robert Wood Johnson Medical School, 08854 Piscataway, NJ, USA

关键词: BRCA2;    BRCA1;    Hereditary breast and ovarian cancer syndrome;    Genetic testing;    Family communication;   

Others  :  806478
DOI  :  10.1186/1897-4287-10-4

 received in 2012-01-12, accepted in 2012-04-12,  发布年份 2012

【 摘 要 】

Background

Individuals who carry deleterious BRCA mutations face significantly elevated risks of breast, ovarian, and other cancers. These individuals are also responsible for informing relatives of their increased risk for carrying the family BRCA mutation. Few interventions have been developed to facilitate this family communication process.

Methods

We developed the Sharing Risk Information Tool (ShaRIT), a personalized educational intervention, to support BRCA carriers as they discuss BRCA positive results and their implications with relatives. We conducted a pilot study of 19 BRCA carriers identified through the University of California San Francisco Cancer Risk Program. Our study had two aims: 1) to assess the feasibility and acceptability of ShaRIT, and 2) describe characteristics associated with increased family communication and BRCA testing. Participants in our study were divided into two groups: those who had not received ShaRIT as part of their genetic counseling protocol (control group, n = 10) and those who received ShaRIT (n = 9).

Results

All 9 women who received ShaRIT reported that it was a useful resource. Characteristics associated with increased sharing and testing included: female gender, degree of relationship, and frequency of communication. Increased pedigree knowledge showed a trend toward higher rates of sharing.

Conclusions

Both participants and genetic counselors considered ShaRIT a well-received, comprehensive tool for disseminating individual risk information and clinical care guidelines to Hereditary Breast and Ovarian Cancer Syndrome families. Because of this, ShaRIT has been incorporated as standard of care at our institution. In the future we hope to evaluate the effects of ShaRIT on family communication and family testing in larger populations of BRCA positive families.

【 授权许可】

   
2012 Kardashian et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Nelson HD, Huffman LH, Fu R, Harris EL: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Inter Med 2005, 143:362-379.
• [2]Berliner JL, Fay AM: Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Counsel 2007, 16:241-260.
• [3]Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN: Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010, 8:562-594.
• [4]Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
• [5]King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.
• [6]John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS: Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. J Am Med Assoc 2007, 298:2869-2876.
• [7]Edlich RF, Winters KL, Lin KY: Breast cancer and ovarian cancer genetics. J Long Term Eff Med Implants 2005, 15:533-545.
• [8]Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA: The "duty to warn" a patient's family members about hereditary disease risks. J Am Med Assoc 2004, 292:1469-1473.
• [9]Landsbergen K, Verhaak C, Kraaimaat F, Hoogerbrugge N: Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. Fam Cancer 2005, 4:115-119.
• [10]McGivern B, Everett J, Yager GG, Baumiller RC, Hafertepen A, Saal HM: Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med 2004, 6:503-509.
• [11]Wagner Costalas J, Itzen M, Malick J, Babb JS, Bove B, Godwin AK, Daly MB: Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet 2003, 119C:11-18.
• [12]Patenaude AF, Dorval M, DiGianni LS, Schneider KA, Chittenden A, Garber JE: Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 2006, 24:700-706.
• [13]Hughes C, Lerman C, Schwartz M, Peshkin BN, Wenzel L, Narod S, Corio C, Tercyak KP, Hanna D, Isaacs C, Main D: All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 2002, 107:143-150.
• [14]Cheung EL, Olson AD, Yu TM, Han PZ, Beattie MS: Communication of BRCA results and family testing in 1,103 high-risk women. Cancer Epidemiol Biomarkers Prev 2010, 19:2211-2219.
• [15]Finlay E, Stopfer JE, Burlingame E, Evans KG, Nathanson KL, Weber BL, Armstrong K, Rebbeck TR, Domchek SM: Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test 2008, 12:81-91.
• [16]Daly MB, Barsevick A, Miller SM, Buckman R, Costalas J, Montgomery S, Bingler R: Communicating genetic test results to the family: a six-step, skills-building strategy. Fam Community Health 2001, 24:13-26.
• [17]Chivers Seymour K, Addington-Hall J, Lucassen AM, Foster CL: What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 2010, 19:330-342.
• [18]Vos J, Menko F, Jansen AM, van Asperen CJ, Stiggelbout AM, Tibben A: A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer 2011, 10:87-96.
• [19]DudokdeWit AC, Tibben A, Frets PG, Meijers-Heijboer EJ, Devilee P, Klijn JG, Oosterwijk JC, Niermeijer MF: BRCA1 in the family: a case description of the psychological implications. Am J Med Genet 1997, 71:63-71.
• [20]Bradbury AR, Dignam JJ, Ibe CN, Auh SL, Hlubocky FJ, Cummings SA, White M, Olopade OI, Daugherty CK: How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol 2007, 25:3705-3711.
• [21]Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E: Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet 2003, 116A:11-19.
• [22]Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT: What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998, 16:1650-1654.
• [23]MacDonald DJ, Sarna L, van Servellen G, Bastani R, Giger JN, Weitzel JN: Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med 2007, 9:275-282.
• [24]Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J: Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test 2005, 9:306-312.
• [25]Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B: Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000, 9:1251-1254.
• [26]Kieran S, Loescher LJ, Lim KH: The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test 2007, 11:101-110.
• [27]Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, Padonu G, Talarczyk G: Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making 1996, 16:58-64.
• [28]Segal J, Esplen MJ, Toner B, Baedorf S, Narod S, Butler K: An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers. Am J Med Genet A 2004, 125A:267-272.